Generic Drugs Market Research Report: By Type (Simple, Super, Biosimilars), Application (Neurological Diseases, Cardiological Diseases, Metabolic Diseases, Infectious Diseases, Orthopedic Diseases, Genitourinary/Hormonal Diseases, Respiratory Diseases), Route of Administration (Oral, Injection, Cutaneous, Mucosal, Inhalation), Distribution Channel (Indirect, Direct) - Global Industry Analysis and Demand Forecast to 2030

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Research Scope

1.3.1 Market Segmentation by Type

1.3.2 Market Segmentation by Application

1.3.3 Market Segmentation by Route of Administration

1.3.4 Market Segmentation by Distribution Channel

1.3.5 Market Segmentation by Region

1.3.6 Analysis Period

1.3.7 Market Data Reporting Unit

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By region

2.2.1.2 By industry participant

2.2.1.3 By company type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Currency Conversion Rates

2.6 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Market Definition

4.1.1 By Type

4.1.1.1 Simple

4.1.1.2 Super

4.1.1.3 Biosimilars

4.1.2 By Application

4.1.2.1 Neurological diseases

4.1.2.2 Cardiological diseases

4.1.2.3 Metabolic diseases

4.1.2.4 Infectious diseases

4.1.2.5 Orthopedic diseases

4.1.2.6 Respiratory diseases

4.1.2.7 Genitourinary/hormonal diseases

4.1.2.8 Others

4.1.3 By Route of Administration

4.1.3.1 Oral

4.1.3.2 Injection

4.1.3.3 Cutaneous

4.1.3.4 Mucosal

4.1.3.5 Inhalation

4.1.3.6 Others

4.1.4 By Distribution Channel

4.1.4.1 Indirect

4.1.4.2 Direct

4.2 Market Dynamics

4.2.1 Trends

4.2.1.1 Shift in preference toward generic drugs

4.2.1.2 Increasing product launches

4.2.1.3 Rising number of collaborations and partnerships

4.2.1.4 Increasing number of mergers and acquisitions

4.2.2 Drivers

4.2.2.1 Increasing ageing population

4.2.2.2 Patent expiration of blockbuster drugs

4.2.2.3 Growing prevalence of acute and chronic diseases

4.2.2.4 Rising R&D expenditure of biotech and pharma companies

4.2.2.5 Impact analysis of drivers on market forecast

4.2.3 Restraints

4.2.3.1 High marketing of branded drugs overshadows generics

4.2.3.2 Preference of physicians toward branded drugs

4.2.3.3 Impact analysis of restraints on market forecast

4.2.4 Opportunities

4.2.4.1 Supportive regulations for generics

4.3 Impact of COVID-19

4.3.1 Supply Side Analysis

4.3.1.1 Current scenario of major manufactures and exporters of generic products

4.3.1.2 Situation of lockdown and workforce availability

4.3.1.3 Production scenario

4.3.1.4 Situation of major countries supplying generic drugs

4.3.2 Demand Side Analysis

4.4 Porter’s Five Forces Analysis

4.4.1 Bargaining Power of Buyers

4.4.2 Bargaining Power of Suppliers

4.4.3 Intensity of Rivalry

4.4.4 Threat of New Entrants

4.4.5 Threat of Substitutes

Chapter 5. Global Market Size and Forecast

5.1 By Type

5.2 By Application

5.3 By Route of Administration

5.4 By Distribution Channel

5.5 By Region

Chapter 6. North America Market Size and Forecast

6.1 By Type

6.2 By Application

6.3 By Route of Administration

6.4 By Distribution Channel

6.5 By Country

Chapter 7. Europe Market Size and Forecast

7.1 By Type

7.2 By Application

7.3 By Route of Administration

7.4 By Distribution Channel

7.5 By Country

Chapter 8. APAC Market Size and Forecast

8.1 By Type

8.2 By Application

8.3 By Route of Administration

8.4 By Distribution Channel

8.5 By Country

Chapter 9. LATAM Market Size and Forecast

9.1 By Type

9.2 By Application

9.3 By Route of Administration

9.4 By Distribution Channel

9.5 By Country

Chapter 10. MEA Market Size and Forecast

10.1 By Type

10.2 By Application

10.3 By Route of Administration

10.4 By Distribution Channel

10.5 By Country

Chapter 11. Competitive Landscape

11.1 Strategic Developments of Key Players

11.1.1 Product Launches and Approvals

11.1.2 Partnerships

11.2 Major Players and Their Offerings

Chapter 12. Company Profiles

12.1 Cipla Ltd.

12.1.1 Business Overview

12.1.2 Product and Service Offerings

12.1.3 Key Financial Summary

12.2 Dr. Reddy’s Laboratories Ltd.

12.2.1 Business Overview

12.2.2 Product and Service Offerings

12.2.3 Key Financial Summary

12.3 Alkem Laboratories Limited

12.3.1 Business Overview

12.3.2 Product and Service Offerings

12.3.3 Key Financial Summary

12.4 Teva Pharmaceutical Industries Limited

12.4.1 Business Overview

12.4.2 Product and Service Offerings

12.4.3 Key Financial Summary

12.5 Mylan N.V.

12.5.1 Business Overview

12.5.2 Product and Service Offerings

12.5.3 Key Financial Summary

12.6 Lupin Limited

12.6.1 Business Overview

12.6.2 Product and Service Offerings

12.6.3 Key Financial Summary

12.7 Endo International plc

12.7.1 Business Overview

12.7.2 Product and Service Offerings

12.7.3 Key Financial Summary

12.8 Aurobindo Pharma Limited

12.8.1 Business Overview

12.8.2 Product and Service Offerings

12.8.3 Key Financial Summary

12.9 STADA Arzneimittel AG

12.9.1 Business Overview

12.9.2 Product and Service Offerings

12.9.3 Key Financial Summary

12.10 Hikma Pharmaceuticals plc

12.10.1 Business Overview

12.10.2 Product and Service Offerings

12.10.3 Key Financial Summary

12.11 Sawai Pharmaceutical Co. Ltd.

12.11.1 Business Overview

12.11.2 Product and Service Offerings

12.11.3 Key Financial Summary

12.12 Piramal Enterprises Ltd.

12.12.1 Business Overview

12.12.2 Product and Service Offerings

12.12.3 Key Financial Summary

12.13 Mallinckrodt plc

12.13.1 Business Overview

12.13.2 Product and Service Offerings

12.13.3 Key Financial Summary

12.14 Torrent Pharmaceuticals Ltd.

12.14.1 Business Overview

12.14.2 Product and Service Offerings

12.14.3 Key Financial Summary

12.15 Amneal Pharmaceuticals Inc.

12.15.1 Business Overview

12.15.2 Product and Service Offerings

12.15.3 Key Financial Summary

12.16 Taro Pharmaceutical Industries Ltd.

12.16.1 Business Overview

12.16.2 Product and Service Offerings

12.16.3 Key Financial Summary

12.17 Perrigo Company plc

12.17.1 Business Overview

12.17.2 Product and Service Offerings

12.17.3 Key Financial Summary

12.18 Alvogen

12.18.1 Business Overview

12.18.2 Product and Service Offerings

12.19 Nichi-Iko Pharmaceutical Co. Ltd.

12.19.1 Business Overview

12.19.2 Product and Service Offerings

12.19.3 Key Financial Summary

12.20 Glenmark Life Sciences Limited

12.20.1 Business Overview

12.20.2 Product and Service Offerings

12.20.3 Key Financial Summary

12.21 Amphastar Pharmaceuticals Inc.

12.21.1 Business Overview

12.21.2 Product and Service Offerings

12.21.3 Key Financial Summary

12.22 MSN Labs

12.22.1 Business Overview

12.22.2 Product and Service Offerings

12.23 CUSTOPHARM INC.

12.23.1 Business Overview

12.23.2 Product and Service Offerings

12.24 Cadila Healthcare Ltd.

12.24.1 Business overview

12.24.2 Product and Service Offerings

12.24.3 Key Financial Summary

12.25 Pfizer Inc.

12.25.1 Business Overview

12.25.2 Product and Service Offerings

12.25.3 Key Financial Summary

12.26 Sanofi

12.26.1 Business Overview

12.26.2 Product and Service Offerings

12.26.3 Key Financial Summary

12.27 Bausch Health Companies Inc.

12.27.1 Business Overview

12.27.2 Product and Service Offerings

12.27.3 Key Financial Summary

Chapter 13. Appendix

13.1 Abbreviations

13.2 Sources and References

13.3 Related Reports

 

LIST OF TABLES

 

TABLE 1 VALUE MARKET SIZE ANALYSIS PERIOD

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 GLOBAL GENERIC DRUGS MARKET, BY TYPE, $B (2014–2019)

TABLE 5 GLOBAL GENERIC DRUGS MARKET, BY TYPE, $B (2020–2030)

TABLE 6 GLOBAL GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2019)

TABLE 7 GLOBAL GENERIC DRUGS MARKET, BY APPLICATION, $B (2020–2030)

TABLE 8 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2019)

TABLE 9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020–2030)

TABLE 10 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2019)

TABLE 11 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020–2030)

TABLE 12 GLOBAL GENERIC DRUGS MARKET, BY REGION, $B (2014–2019)

TABLE 13 GLOBAL GENERIC DRUGS MARKET, BY REGION, $B (2020–2030)

TABLE 14 NORTH AMERICA GENERIC DRUGS MARKET, BY TYPE, $B (2014–2019)

TABLE 15 NORTH AMERICA GENERIC DRUGS MARKET, BY TYPE, $B (2020–2030)

TABLE 16 NORTH AMERICA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2019)

TABLE 17 NORTH AMERICA GENERIC DRUGS MARKET, BY APPLICATION, $B (2020–2030)

TABLE 18 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2019)

TABLE 19 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020–2030)

TABLE 20 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2019)

TABLE 21 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020–2030)

TABLE 22 NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2019)

TABLE 23 NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, $B (2020–2030)

TABLE 24 EUROPE GENERIC DRUGS MARKET, BY TYPE, $B (2014–2019)

TABLE 25 EUROPE GENERIC DRUGS MARKET, BY TYPE, $B (2020–2030)

TABLE 26 EUROPE GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2019)

TABLE 27 EUROPE GENERIC DRUGS MARKET, BY APPLICATION, $B (2020–2030)

TABLE 28 EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2019)

TABLE 29 EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020–2030)

TABLE 30 EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2019)

TABLE 31 EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020–2030)

TABLE 32 EUROPE GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2019)

TABLE 33 EUROPE GENERIC DRUGS MARKET, BY COUNTRY, $B (2020–2030)

TABLE 34 APAC GENERIC DRUGS MARKET, BY TYPE, $B (2014–2019)

TABLE 35 APAC GENERIC DRUGS MARKET, BY TYPE, $B (2020–2030)

TABLE 36 APAC GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2019)

TABLE 37 APAC GENERIC DRUGS MARKET, BY APPLICATION, $B (2020–2030)

TABLE 38 APAC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2019)

TABLE 39 APAC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020–2030)

TABLE 40 APAC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2019)

TABLE 41 APAC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020–2030)

TABLE 42 APAC GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2019)

TABLE 43 APAC GENERIC DRUGS MARKET, BY COUNTRY, $B (2020–2030)

TABLE 44 LATAM GENERIC DRUGS MARKET, BY TYPE, $B (2014–2019)

TABLE 45 LATAM GENERIC DRUGS MARKET, BY TYPE, $B (2020–2030)

TABLE 46 LATAM GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2019)

TABLE 47 LATAM GENERIC DRUGS MARKET, BY APPLICATION, $B (2020–2030)

TABLE 48 LATAM GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2019)

TABLE 49 LATAM GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020–2030)

TABLE 50 LATAM GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2019)

TABLE 51 LATAM GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020–2030)

TABLE 52 LATAM GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2019)

TABLE 53 LATAM GENERIC DRUGS MARKET, BY COUNTRY, $B (2020–2030)

TABLE 54 MEA GENERIC DRUGS MARKET, BY TYPE, $B (2014–2019)

TABLE 55 MEA GENERIC DRUGS MARKET, BY TYPE, $B (2020–2030)

TABLE 56 MEA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2019)

TABLE 57 MEA GENERIC DRUGS MARKET, BY APPLICATION, $B (2020–2030)

TABLE 58 MEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2019)

TABLE 59 MEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2020–2030)

TABLE 60 MEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2019)

TABLE 61 MEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2020–2030)

TABLE 62 MEA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2019)

TABLE 63 MEA GENERIC DRUGS MARKET, BY COUNTRY, $B (2020–2030)

TABLE 64 MAJOR PLAYERS AND THEIR OFFERINGS

TABLE 65 CIPLA LTD. – AT A GLANCE

TABLE 66 CIPLA LTD. – KEY FINANCIAL SUMMARY

TABLE 67 DR. REDDY’S LABORATORIES LTD. – AT A GLANCE

TABLE 68 DR. REDDY’S LABORATORIES LTD. – KEY FINANCIAL SUMMARY

TABLE 69 ALKEM LABORATORIES LIMITED – AT A GLANCE

TABLE 70 ALKEM LABORATORIES LIMITED – KEY FINANCIAL SUMMARY

TABLE 71 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – AT A GLANCE

TABLE 72 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – KEY FINANCIAL SUMMARY

TABLE 73 MYLAN N.V. – AT A GLANCE

TABLE 74 MYLAN N.V. – KEY FINANCIAL SUMMARY

TABLE 75 LUPIN LIMITED – AT A GLANCE

TABLE 76 LUPIN LIMITED – KEY FINANCIAL SUMMARY

TABLE 77 ENDO INTERNATIONAL PLC – AT A GLANCE

TABLE 78 ENDO INTERNATIONAL PLC – KEY FINANCIAL SUMMARY

TABLE 79 AUROBINDO PHARMA LIMITED – AT A GLANCE

TABLE 80 AUROBINDO PHARMA LIMITED – KEY FINANCIAL SUMMARY

TABLE 81 STADA ARZNEIMITTEL AG – AT A GLANCE

TABLE 82 STADA ARZNEIMITTEL AG – KEY FINANCIAL SUMMARY

TABLE 83 HIKMA PHARMACEUTICALS PLC – AT A GLANCE

TABLE 84 HIKMA PHARMACEUTICALS PLC – KEY FINANCIAL SUMMARY

TABLE 85 SAWAI PHARMACEUTICAL CO. LTD. – AT A GLANCE

TABLE 86 SAWAI PHARMACEUTICAL CO. LTD. – KEY FINANCIAL SUMMARY

TABLE 87 PIRAMAL ENTERPRISES LTD. – AT A GLANCE

TABLE 88 PIRAMAL ENTERPRISES LTD. – KEY FINANCIAL SUMMARY

TABLE 89 MALLINCKRODT PLC – AT A GLANCE

TABLE 90 MALLINCKRODT PLC – KEY FINANCIAL SUMMARY

TABLE 91 TORRENT PHARMACEUTICALS LTD. – AT A GLANCE

TABLE 92 TORRENT PHARMACEUTICALS LTD. – KEY FINANCIAL SUMMARY

TABLE 93 AMNEAL PHARMACEUTICALS INC. – AT A GLANCE

TABLE 94 AMNEAL PHARMACEUTICALS INC. – KEY FINANCIAL SUMMARY

TABLE 95 TARO PHARMACEUTICAL INDUSTRIES LTD. – AT A GLANCE

TABLE 96 TARO PHARMACEUTICAL INDUSTRIES LTD. – KEY FINANCIAL SUMMARY

TABLE 97 PERRIGO COMPANY PLC – AT A GLANCE

TABLE 98 PERRIGO COMPANY PLC – KEY FINANCIAL SUMMARY

TABLE 99 ALVOGEN – AT A GLANCE

TABLE 100 NICHI-IKO PHARMACEUTICAL CO. LTD. – AT A GLANCE

TABLE 101 NICHI-IKO PHARMACEUTICAL CO. LTD. – KEY FINANCIAL SUMMARY

TABLE 102 GLENMARK LIFE SCIENCES LIMITED – AT A GLANCE

TABLE 103 GLENMARK LIFE SCIENCES LIMITED – KEY FINANCIAL SUMMARY

TABLE 104 AMPHASTAR PHARMACEUTICALS INC. – AT A GLANCE

TABLE 105 AMPHASTAR PHARMACEUTICALS INC. – KEY FINANCIAL SUMMARY

TABLE 106 MSN LABS – AT A GLANCE

TABLE 107 CUSTOPHARM INC. – AT A GLANCE

TABLE 108 CADILA HEALTHCARE LTD. – AT A GLANCE

TABLE 109 CADILA HEALTHCARE LTD. – KEY FINANCIAL SUMMARY

TABLE 110 PFIZER INC. – AT A GLANCE

TABLE 111 PFIZER INC. – KEY FINANCIAL SUMMARY

TABLE 112 SANOFI – AT A GLANCE

TABLE 113 SANOFI – KEY FINANCIAL SUMMARY

TABLE 114 BAUSCH HEALTH COMPANIES INC. – AT A GLANCE

TABLE 115 BAUSCH HEALTH COMPANIES INC. – KEY FINANCIAL SUMMARY

 

LIST OF FIGURES

 

FIG 1 RESEARCH SCOPE

FIG 2 RESEARCH METHODOLOGY

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT

FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE

FIG 6 DATA TRIANGULATION APPROACH

FIG 7 CURRENCY CONVERSION RATES FOR USD (2019)

FIG 8 GLOBAL GENERIC DRUGS MARKET SUMMARY

FIG 9 BARGAINING POWER OF BUYERS

FIG 10 BARGAINING POWER OF SUPPLIERS

FIG 11 INTENSITY OF RIVALRY

FIG 12 THREAT OF NEW ENTRANTS

FIG 13 THREAT OF SUBSTITUTES

FIG 14 SNAPSHOT OF GLOBAL GENERIC DRUGS MARKET

FIG 15 GLOBAL GENERIC DRUGS MARKET, BY TYPE, $B (2014–2030)

FIG 16 GLOBAL GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2030)

FIG 17 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2030)

FIG 18 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2030)

FIG 19 WORLDWIDE MAJOR MARKETS FOR GENERIC DRUGS

FIG 20 GLOBAL GENERIC DRUGS MARKET, BY REGION, $B (2014–2030)

FIG 21 NORTH AMERICA GENERIC DRUGS MARKET SNAPSHOT

FIG 22 NORTH AMERICA GENERIC DRUGS MARKET, BY TYPE, $B (2014–2030)

FIG 23 NORTH AMERICA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2030)

FIG 24 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2030)

FIG 25 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2030)

FIG 26 NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2030)

FIG 27 EUROPE GENERIC DRUGS MARKET SNAPSHOT

FIG 28 EUROPE GENERIC DRUGS MARKET, BY TYPE, $B (2014–2030)

FIG 29 EUROPE GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2030)

FIG 30 EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2030)

FIG 31 EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2030)

FIG 32 EUROPE GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2030)

FIG 33 APAC GENERIC DRUGS MARKET SNAPSHOT

FIG 34 APAC GENERIC DRUGS MARKET, BY TYPE, $B (2014–2030)

FIG 35 APAC GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2030)

FIG 36 APAC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2030)

FIG 37 APAC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2030)

FIG 38 APAC GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2030)

FIG 39 LATAM GENERIC DRUGS MARKET SNAPSHOT

FIG 40 LATAM GENERIC DRUGS MARKET, BY TYPE, $B (2014–2030)

FIG 41 LATAM GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2030)

FIG 42 LATAM GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2030)

FIG 43 LATAM GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2030)

FIG 44 LATAM GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2030)

FIG 45 MEA GENERIC DRUGS MARKET SNAPSHOT

FIG 46 MEA GENERIC DRUGS MARKET, BY TYPE, $B (2014–2030)

FIG 47 MEA GENERIC DRUGS MARKET, BY APPLICATION, $B (2014–2030)

FIG 48 MEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, $B (2014–2030)

FIG 49 MEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, $B (2014–2030)

FIG 50 MEA GENERIC DRUGS MARKET, BY COUNTRY, $B (2014–2030)

FIG 51 CIPLA LTD. – REVENUE SPLIT BY THERAPY AND GEOGRAPHY (2019)

FIG 52 DR. REDDY’S LABORATORIES LTD. – REVENUE SPLIT BY BUSSINESS SEGMENT AND GEOGRAPHY (2019)

FIG 53 ALKEM LABORATORIES LIMITED – REVENUE SPLIT BY GEOGRAPHY (2019)

FIG 54 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – REVENUE SPLIT BY GEOGRAPHY (2019)

FIG 55 MYLAN N.V. – REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2019)

FIG 56 LUPIN LIMITED – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)

FIG 57 ENDO INTERNATIONAL PLC – REVENUE SPLIT BY DIVISION (2019)

FIG 58 AUROBINDO PHARMA LIMITED – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 59 STADA ARZNEIMITTEL AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 60 HIKMA PHARMACEUTICALS PLC – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2019)

FIG 61 SAWAI PHARMACEUTICAL CO. LTD. – REVENUE SPLIT BY GEOGRAPHY (2019)

FIG 62 PIRAMAL ENTERPRISES LTD. – REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2019)

FIG 63 MALLINCKRODT PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 64 TORRENT PHARMACEUTICALS LTD. – REVENUE SPLIT BY GEOGRAPHY (2019)

FIG 65 AMNEAL PHARMACEUTICALS INC. – REVENUE SPLIT BY SEGMENT (2019)

FIG 66 TARO PHARMACEUTICAL INDUSTRIES LTD. – REVENUE SPLIT BY GEOGRAPHY (2020)

FIG 67 PERRIGO COMPANY PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 68 NICHI-IKO PHARMACEUTICAL CO. LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 69 GLENMARK LIFE SCIENCES LIMITED – REVENUE SPLIT BY GEOGRAPHY (2019)

FIG 70 AMPHASTAR PHARMACEUTICALS INC. – REVENUE SPLIT BY GEOGRAPHY (2019)

FIG 71 CADILA HEALTHCARE LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 72 PFIZER INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 73 SANOFI – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 74 BAUSCH HEALTH COMPANIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)